AU2851701A - Use of thrombin receptor antagonists against gliosis - Google Patents

Use of thrombin receptor antagonists against gliosis

Info

Publication number
AU2851701A
AU2851701A AU28517/01A AU2851701A AU2851701A AU 2851701 A AU2851701 A AU 2851701A AU 28517/01 A AU28517/01 A AU 28517/01A AU 2851701 A AU2851701 A AU 2851701A AU 2851701 A AU2851701 A AU 2851701A
Authority
AU
Australia
Prior art keywords
gliosis
receptor antagonists
thrombin receptor
antagonists against
thrombin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU28517/01A
Inventor
Armelle Nathalie Francoise Pindon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2851701A publication Critical patent/AU2851701A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU28517/01A 2000-02-07 2001-01-29 Use of thrombin receptor antagonists against gliosis Abandoned AU2851701A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00200405 2000-02-07
EP00200405 2000-02-07
PCT/EP2001/000945 WO2001058959A1 (en) 2000-02-07 2001-01-29 Use of thrombin receptor antagonists against gliosis

Publications (1)

Publication Number Publication Date
AU2851701A true AU2851701A (en) 2001-08-20

Family

ID=8170987

Family Applications (1)

Application Number Title Priority Date Filing Date
AU28517/01A Abandoned AU2851701A (en) 2000-02-07 2001-01-29 Use of thrombin receptor antagonists against gliosis

Country Status (2)

Country Link
AU (1) AU2851701A (en)
WO (1) WO2001058959A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108469427A (en) * 2018-02-07 2018-08-31 大连大学 A method of the plasma-induced intracellular absolutely calcium ion concentration of characterization

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001125A (en) * 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108469427A (en) * 2018-02-07 2018-08-31 大连大学 A method of the plasma-induced intracellular absolutely calcium ion concentration of characterization

Also Published As

Publication number Publication date
WO2001058959A1 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
IL153308A0 (en) Thrombin receptor antagonists
AU2002341834A1 (en) Antagonists
AU2001250205A1 (en) Prostaglandin d2 receptor antagonists
AU2001246402A1 (en) Polypeptides having haloperoxidase activity
AU2001246403A1 (en) Polypeptides having haloperoxidase activity
AU2001246401A1 (en) Polypeptides having haloperoxidase activity
AU2002367424A1 (en) Androgen receptor antagonists
AU2002235224A1 (en) Muscarinic antagonists
AU2001264657A1 (en) Crf receptor antagonists
AU2001234741A1 (en) Integrin antagonists
AU2002247725A1 (en) Antagonists fpr alpha4beta7-integrin
AU2002365655A1 (en) 5-ht7 receptor antagonists
AU2001290772A1 (en) Alpha v integrin receptor antagonists
AU2001286409A1 (en) N-methyl-d-aspartate receptor antagonists
AU2001245724A1 (en) Il-8 receptor antagonists
AU2001240021A1 (en) Diazafluorenone il-8 receptor antagonists
AU2001264920A1 (en) Therapeutic uses of il-1 receptor antagonist
AU2002226048A1 (en) Urotensin-ii receptor antagonists
AU2002216079A1 (en) Bombesin receptor antagonists
AU2001243351A1 (en) Il-8 receptor antagonists
AU2002239506A1 (en) Urotensin-ii receptor antagonists
AU2001225663A1 (en) A composition comprising a combination of receptor agonists and antagonists
AU2001249573A1 (en) Chemokine receptor antagonists
AUPQ570100A0 (en) Beta-alanine derivatives and their use as receptor antagonists
AU2001263288A1 (en) Crf receptor antagonists

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase